Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average.

Pharmaceuticals giant Pfizer closed Tuesday's session nearly 5% in the green, after it issued an upbeat full-year outlook for ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...

The dramatic rise is another peak in Teva's recovery over the past year and rewards investors after a long period of ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Free Report) was the recipient of unusually large options trading on ...

Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could ...

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares. After Phase 2 ...

Barclays analyst Balaji Prasad raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The ...

Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a modest uptick, ending the day at $20.88 which represents a slight increase of $4.37 or 26.47% from the prior close of $16.51. The stock opened at ...